RecruitingNCT06680778

Pro-active Monitoring of Vital Signs in Oncology Patients Using a Smartwatch

The Use of Proa-active Monitoring by Measuring Vital Signs Using a Fitbit for a 3-month Period Before, During, and After Chemotherapy in Patients With Cancer


Sponsor

Erasmus Medical Center

Enrollment

175 participants

Start Date

Jul 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this single center prospective observational study is to determine the effect of chemotherapy on (the change in) vital parameters. The main question it aims to answer are: Can changes in vital parameters be measured by using a Fitbit in patients with cancer while undergoing chemotherapy. Participants will be asked to wear a Fitbit for the first two cycles of chemotherapy to evaluate the changes in vital parameters.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Age ≥18 years;
  • Diagnosis of stomach or esophageal cancer with an indication of starting chemotherapy
  • Knowledge how to handle a Fitbit
  • Mastery of Dutch language
  • Able and willing to give written informed consent

Exclusion Criteria2

  • Cognitive disorders or severe emotional instability
  • Already participating in an exercise trial

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEProactive Monitoring

Proactive monitoring of vital signs for the duration of the first two cycles of chemotherapy by using a Fitbit


Locations(1)

Erasmus University Medical Center

Rotterdam, South Holland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06680778


Related Trials